Differences

This shows you the differences between two versions of the page.

--- sarah_wilson [2022/04/20 10:24]
liam [Public Health Agency of Canada]
+++ sarah_wilson [2022/07/28 19:06] (current)
liam [Sarah Wilson]
@@ Line 3: / Line 3: @@
 {{ ::expert-sarah-wilson.png?200|}}
-Dr. **Sarah Wilson** is a Canadian [[public health]] physicians and epidemiologist based in Toronto, Ontario.
+Dr. **Sarah Wilson** is a Canadian [[public health]] physician and epidemiologist based in [[canada:ontario:Toronto]], [[canada:Ontario]].
 ===== Education =====
@@ Line 9: / Line 9: @@
 Wilson received a Doctor of Medicine from the [[University of Toronto]], and a Master of Science in Public Health from the [[London School of Hygiene and Tropical Medicine]]. She is a certificant of the [[Canadian College of Family Medicine]] (CCFP).
-Wilson is a Fellow of the [[Royal College of Physicians and Surgeons of Canada]] in [[Public Health]] and [[Preventive Medicine]] and a graduate of the [[Canadian Field Epidemiology Program]].
+Wilson is a Fellow of the [[Royal College of Physicians and Surgeons of Canada]] in [[Public Health]] and [[Preventative Medicine]].
+==== Canadian Field Epidemiology Program ====
+Wilson is a graduate of the [[Canadian Field Epidemiology Program]]. The CFEP "mobilizes field epidemiologists anywhere they are needed within Canada or around the world, supporting public health organizations as they respond to urgent public health events."((Public Health Agency of Canada. (2017, November 16). //Canadian Field Epidemiology Program.// Government of Canada. https://archive.ph/Ci8Yr))
+CFEP is also a partner in the [[Training Programs in Epidemiology and Public Health Interventions Network]] (TEPHINET) and occasionally responds to requests from the [[World Health Organization]]'s [[Global Outbreak Alert and Response Network]] (GOARN). As a result of these connections, Field Epidemiologists may have the opportunity to present their work at international conferences and support investigations outside Canada.
 ===== Career and Affiliations =====
@@ Line 20: / Line 25: @@
 She represents PHO as a member of [[Immunization Canada]] as of November 2019.
+==== Women's College Hospital ====
+Wilson is a clinical associate at [[Women's College Hospital]].((//Sarah Wilson.// LinkedIn. Retrieved April 20, 2022, from https://www.linkedin.com/in/sarah-wilson-163a4812/)) WCH is funded through their foundation by [[pharmaceutical_companies:Allergan]], [[pharmaceutical_companies:Amgen]], [[pharmaceutical_companies:Bayer]], [[medical_technology_companies:Becton Dickinson and Company|BD]], and
+[[Canadian Cancer Society]].((//Donor Listings.// Women’s College Hospital Foundation. Retrieved January 27, 2022, from https://archive.ph/U1euy))
 ==== University of Toronto ====
 Wilson is an Assistant Professor at the [[Dalla Lana School of Public Health]] at the [[University of Toronto]].((//Wilson, Sarah.// Dalla Lana School of Public Health. Retrieved April 20, 2022, from https://archive.ph/1xI4C)) She is a member of U of T's [[Centre for Vaccine Preventable Diseases]] as a member of its Education committee since April 2017.
+==== Canadian Immunization Research Network ====
+Wilson is a researcher at the [[Canadian Immunization Research Network]] (CIRN), participating as a co-investigator in their Reference Laboratory and Provincial Collaborative networks.((//Annual report 2019-2020.// Canadian Immunization Research Network. Retrieved April 20, 2022, from https://web.archive.org/web/20220420233925/https://cirnetwork.ca/wp-content/uploads/2021/08/AR.2019-20.Final_.pdf)) ((//Sarah Wilson.// (2018, February 23). CIRN | Canadian Immunization Research Network. https://web.archive.org/web/20220420234816/https://cirnetwork.ca/researcher/sarah-wilson/)) CIRN is funded by [[pharmaceutical_companies:GlaxoSmithKline]], [[pharmaceutical_companies:Novartis]], [[pharmaceutical_companies:Pfizer]], [[pharmaceutical_companies:Sanofi]], and [[pharmaceutical_companies:VBI Vaccines]].
 ==== ICES ====
 Wilson is an Adjunct Scientist at the [[Institute for Clinical Evaluative Studies]] (ICES).((//Sarah Wilson.// (2016, May 11). Wayback Machine; ICES. https://archive.ph/DPtpV))
 ==== Public Health Agency of Canada ====
 Wilson is a member of the [[National Advisory Committee on Immunization]] (NACI), where she was responsible for initially approving [[COVID-19 vaccines]] in Canada.((//National Advisory Committee on Immunization (NACI): Membership and representation.// (2020, December 18). Wayback Machine; Government of Canada. https://web.archive.org/web/20201218222110/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/naci-membership-representation.html))
-She is also a member of the Vaccine Safety Working Group under the Vaccine Surveillance Reference Group (VSRG) of the [[COVID-19 Immunity Task Force]].((//Vaccine surveillance Reference group (VSRG).// COVID-19 Immunity Task Force. Retrieved March 21, 2022, from https://web.archive.org/web/20220121232011/http://www.covid19immunitytaskforce.ca/vaccine-surveillance-reference-group-vsrg/))
+She is also a member of the Vaccine Safety Working Group under the [[Vaccine Surveillance Reference Group]] (VSRG) of the [[COVID-19 Immunity Task Force]].((//Vaccine surveillance Reference group (VSRG).// COVID-19 Immunity Task Force. Retrieved March 21, 2022, from https://web.archive.org/web/20220121232011/http://www.covid19immunitytaskforce.ca/vaccine-surveillance-reference-group-vsrg/))
 ===== Research =====
@@ Line 38: / Line 53: @@
 Wilson has received research funding from the [[Public Health Agency of Canada]], the [[COVID-19
-Immunity Task Force]], and the [[Canadian Institutes of Health Research]] (CIHR) through the [[Canadian Immunization Research Network]] (CIRN).((Wilson, S. E., Quach, S., MacDonald, S. E., Naus, M., Deeks, S. L., Crowcroft, N. S., Mahmud, S. M., Tran, D., Kwong, J., Tu, K., Gilbert, N. L., Johnson, C., & Desai, S. (2017). //Methods used for immunization coverage assessment in Canada, a Canadian Immunization Research Network (CIRN) study.// Human Vaccines & Immunotherapeutics, 13(8), 1928–1936. https://doi.org/10.1080/21645515.2017.1319022))
+Immunity Task Force]], [[Ontario Health Data Platform]], and the [[Canadian Institutes of Health Research]] (CIHR) through the [[Canadian Immunization Research Network]] (CIRN).((Wilson, S. E., Quach, S., MacDonald, S. E., Naus, M., Deeks, S. L., Crowcroft, N. S., Mahmud, S. M., Tran, D., Kwong, J., Tu, K., Gilbert, N. L., Johnson, C., & Desai, S. (2017). //Methods used for immunization coverage assessment in Canada, a Canadian Immunization Research Network (CIRN) study.// Human Vaccines & Immunotherapeutics, 13(8), 1928–1936. https://doi.org/10.1080/21645515.2017.1319022)) ((Chung, H., He, S., Nasreen, S., Sundaram, M. E., Buchan, S. A., Wilson, S. E., Chen, B., Calzavara, A., Fell, D. B., Austin, P. C., Wilson, K., Schwartz, K. L., Brown, K. A., Gubbay, J. B., Basta, N. E., Mahmud, S. M., Righolt, C. H., Svenson, L. W., MacDonald, S. E., & Janjua, N. Z. (2021). //Effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study.// BMJ (Clinical Research Ed.), 374, n1943. https://doi.org/10.1136/bmj.n1943))